Related Experiment Video
Updated: Aug 20, 2026

Aip1p Dynamics Are Altered by the R256H Mutation in Actin
Published on: July 30, 2014
New and unexpected: forkhead meets ARF
Robert H Costa1, Vladimir V Kalinichenko, Michael L Major
1Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, College of Medicine, Chicago, Illinois 60607, USA. robcosta@uic.edu
Abstract:
Recent genetic studies demonstrate that mice deficient in the forkhead box m1b (Foxm1b) transcription factor are highly resistant to developing hepatocellular carcinoma, which is among the most lethal cancers worldwide. In addition, the Foxm1b transcription factor was identified as a novel inhibitory target of the p19ARF tumor suppressor during early stages of liver tumorigenesis, but p19ARF expression is extinguished in hepatic tumors that develop at later stages. Structure-function studies demonstrate that amino acids 26-46 of the p19ARF protein are sufficient to bind Foxm1b and reduce Foxm1b transcriptional activity by targeting it to the nucleolus. A peptide containing amino acids 24-46 of p19ARF, which was modified to enhance cellular uptake, is an effective inhibitor of Foxm1b transcriptional activity and prevents Foxm1b stimulation of anchorage-independent growth of cells on soft agar. Thus, the p19ARF peptide is an effective inhibitor of Foxm1b and represents a potential therapy for hepatocellular carcinoma.
Insights
Mice lacking the Foxm1b transcription factor resist liver cancer. A p19ARF peptide inhibits Foxm1b, offering a potential therapy for hepatocellular carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Hepatocellular carcinoma (HCC) is a lethal cancer.
- Foxm1b (forkhead box m1b) transcription factor promotes HCC.
- p19ARF tumor suppressor inhibits Foxm1b early in tumorigenesis, but its expression is lost in advanced tumors.
Purpose of the Study:
- To investigate the inhibitory mechanism of p19ARF on Foxm1b.
- To evaluate a p19ARF-derived peptide as a potential HCC therapy.
Main Methods:
- Structure-function analysis of p19ARF protein domains.
- Assessment of a modified p19ARF peptide's cellular uptake and inhibitory activity.
- Evaluation of the peptide's effect on Foxm1b-driven anchorage-independent cell growth.
Main Results:
- Amino acids 26-46 of p19ARF bind Foxm1b and inhibit its transcriptional activity by promoting nucleolar targeting.
- A modified p19ARF peptide (amino acids 24-46) effectively inhibits Foxm1b activity.
- This peptide prevents Foxm1b-induced anchorage-independent growth, a hallmark of cancer cells.
Conclusions:
- The p19ARF peptide is a potent inhibitor of Foxm1b transcriptional activity.
- This p19ARF peptide represents a promising therapeutic strategy for hepatocellular carcinoma by targeting Foxm1b.
Related Concept Videos
Restarting Stalled Replication Forks
Restarting Stalled Replication Forks
Generation of Straight or Branched Actin Filaments
Arp2/3 Complex
Arp2/3 complex is a seven-subunit complex consisting of two proteins similar to actin- Arp2 and Arp3, and five other subunits that help keep Arp2 and Arp3 inactive. When required, the complex is...
The DNA Replication Fork
The DNA Replication Fork
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...

